W1004 Cost-Effectiveness Analysis Concerning the Surveillance of Hepatocellular Carcinoma with Contrast Enhanced Ultrasonography

Hironori Tanaka; Hiroko Iijima; Shuhei Nishiguchi; Hideji Nakamura

doi:10.1016/s0016-5085(09)63948-2

W1004 Cost-Effectiveness Analysis Concerning the Surveillance of Hepatocellular Carcinoma with Contrast Enhanced Ultrasonography

Gastroenterology ◽

10.1016/s0016-5085(09)63948-2 ◽

2009 ◽

Vol 136 (5) ◽

pp. A-856

Author(s):

Hironori Tanaka ◽

Hiroko Iijima ◽

Shuhei Nishiguchi ◽

Hideji Nakamura

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Contrast Enhanced ◽

Contrast Enhanced Ultrasonography

Get full-text (via PubEx)

1328: Cost-Effectiveness Analysis Concerning the Surveillance of Hepatocellular Carcinoma with Contrast Enhanced Ultrasonography

Ultrasound in Medicine & Biology ◽

10.1016/j.ultrasmedbio.2009.06.713 ◽

2009 ◽

Vol 35 (8) ◽

pp. S189-S190

Author(s):

Hironori Tanaka ◽

Hiroko Iijima ◽

Shuhei Nisiguchi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Contrast Enhanced ◽

Contrast Enhanced Ultrasonography

Get full-text (via PubEx)

Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography

Hepatology Research ◽

10.1111/j.1872-034x.2011.00936.x ◽

2012 ◽

Vol 42 (4) ◽

pp. 376-384 ◽

Cited By ~ 28

Author(s):

Hironori Tanaka ◽

Hiroko Iijima ◽

Kazuhiro Nouso ◽

Noriaki Aoki ◽

Takashi Iwai ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Liver Cirrhosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Contrast Enhanced ◽

Contrast Enhanced Ultrasonography

Get full-text (via PubEx)

Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: A cost-effectiveness analysis

World Journal of Gastroenterology ◽

10.3748/wjg.v22.i38.8605 ◽

2016 ◽

Vol 22 (38) ◽

pp. 8605 ◽

Cited By ~ 16

Author(s):

Miriama Smajerova ◽

Hana Petrasova ◽

Jirina Little ◽

Petra Ovesna ◽

Tomas Andrasina ◽

...

Keyword(s):

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Focal Liver Lesions ◽

Liver Lesions ◽

Effectiveness Analysis ◽

Contrast Enhanced ◽

Contrast Enhanced Ultrasonography

Get full-text (via PubEx)

P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.05.057 ◽

2021 ◽

Vol 32 ◽

pp. S97

Author(s):

S. Chan ◽

C. Chiang ◽

S. Lee ◽

H. Choi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis

Get full-text (via PubEx)

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International ◽

10.1111/liv.14795 ◽

2021 ◽

Vol 41 (5) ◽

pp. 1097-1104

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

Weiting Liao ◽

Kexun Zhou ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Systemic Treatment ◽

The United States ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Get full-text (via PubEx)

Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Value in Health ◽

10.1016/j.jval.2016.09.2397 ◽

2017 ◽

Vol 20 (3) ◽

pp. 336-344 ◽

Cited By ~ 13

Author(s):

Carla Rognoni ◽

Oriana Ciani ◽

Silvia Sommariva ◽

Rosanna Tarricone

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Real World ◽

Cost Effectiveness Analysis ◽

Real World Data ◽

World Data ◽

Transarterial Radioembolization ◽

Effectiveness Analysis

Get full-text (via PubEx)

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis

PLoS ONE ◽

10.1371/journal.pone.0207132 ◽

2018 ◽

Vol 13 (11) ◽

pp. e0207132 ◽

Cited By ~ 15

Author(s):

Amir Shlomai ◽

Moshe Leshno ◽

Daniel A. Goldstein

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Get full-text (via PubEx)

Imaging diseases of the aorta by MRI: a cost-effectiveness analysis of contrast-enhanced studies compared to non-contrast enhanced angiographic studies

Journal of Cardiovascular Magnetic Resonance ◽

10.1186/1532-429x-14-s1-p45 ◽

2012 ◽

Vol 14 (S1) ◽

Author(s):

Emer Sonnex ◽

Melissa L Grzeszczak ◽

Richard Coulden

Keyword(s):

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Contrast Enhanced

Get full-text (via PubEx)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Journal of Gastroenterology ◽

10.1007/s00535-019-01554-0 ◽

2019 ◽

Vol 54 (6) ◽

pp. 558-570 ◽

Cited By ~ 18

Author(s):

Masahiro Kobayashi ◽

Masatoshi Kudo ◽

Namiki Izumi ◽

Shuichi Kaneko ◽

Mie Azuma ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Get full-text (via PubEx)

PIH31 COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA

Value in Health ◽

10.1016/j.jval.2019.04.831 ◽

2019 ◽

Vol 22 ◽

pp. S187-S188

Author(s):

D. Xiao ◽

S. Zhu ◽

W. Sun ◽

J. Xuan

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Line Therapy

Get full-text (via PubEx)